title: Access to targeted therapies in renal cell cancer.
abstract: There is limited access to targeted therapies for renal cancer in many parts of the western world. This is driven by reimbursement rather than regulatory issues. Indeed, only a small fraction of the global population benefits from unlimited reimbursement of targeted therapies. Dedicated bodies, such as the UK National Institute for Clinical Excellence, assess agents on their cost-effectiveness as well as their efficacy. The results have been disappointing for patients, with the majority of agents being rejected for reimbursement. Despite this trend, there is a general appetite to address cost and value in many part of the world. This article gives a current overview of this rapidly changing field.
authors: Beatson West of Scotland Cancer Centre, Glasgow, UK. r.jones@beatson.gla.ac.uk
authors: Robert
authors: R
authors: Jones
authors: Maria
authors: M
authors: DeSantis
mesh_terms: D020811:Biomedical Technology; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D003362:Cost-Benefit Analysis; D055808:Drug Discovery; D005060:Europe; D017048:Health Care Costs; D006297:Health Services Accessibility; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*